MP Group: Outlook on the CROs for the new-age Biopharma

It is our pleasure to share with you our outlook on the ‘CROs for the new-age Biopharma’. The drug development landscape is rapidly shifting towards complex targets and new drug modalities, with growth in cell & gene therapy and ADC pipeline now outpacing traditional small molecule drug candidates. As a result, the Biopharma cos are seeking CROs that can become an extension of their scientific think-tank, providing intellectual inputs and cutting edge research insights. It will be critical for CROs…

Continue Reading

MP Group – A Global Outlook of HEOR (Health Economics and Outcomes Research) Services

We are glad to share our global outlook on Health Economics and Outcomes Research (HEOR) services. The field of Health Economics and Outcomes Research (HEOR) has undergone a significant transformation, shifting from a supportive role to a prominent position in the launch of drug products in the past decade. With the rising research and development costs, innovative therapeutic approaches and government initiative to curtail healthcare expenditures, we anticipate a persistent rise in the demand for HEOR services to demonstrate the…

Continue Reading

MP Outlook – 2021 and Beyond

At the threshold of this New Year, we are pleased to share the ‘MP Outlook – 2021 and Beyond’ (link to the presentation) where we present our analyses on some of the high-impact areas potentially reshaping BioPharma industry, especially from the learnings due to the pandemic. Some of the key highlights of the presentation are –   BioPharma can no longer afford to spend a decade and a billion dollar in getting a drug to the market. Integration of AI-based platform…

Continue Reading
Close Menu